This "Boring" Dividend King Is Quietly Turning Into a Growth Machine -- and Many Investors Are Missing It
A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect.
Overview
It would be easy to not notice. The company isn't exactly disrupting the pharmaceutical business, after all. In fact, most investors would struggle to name a single drug the company makes.
Just dig deeper. Last quarter's results may be a glimpse of the growth that Johnson & Johnson (NYSE: JNJ) quietly has in store for patient investors.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.